New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 4, 2014
06:37 EDTGTXIGTx raises $21.3M in a private placement
GTx announced today that it has entered into a securities purchase agreement with J.R. Hyde, III, the chairman of GTxs Board of Directors, and The Pyramid Peak Foundation, to issue and sell in a private placement to these purchasers an aggregate of 11,976,048 immediately separable units, comprised of an aggregate of 11,976,048 shares of GTx common stock and warrants to purchase up to 10,179,642 additional shares of common stock. The total purchase price payable to GTx for the units is $21,272,455.42, or approximately $1.77625 per unit. The warrants, which may only be exercised for cash, will have a per share exercise price of $1.67 and a one year term.
News For GTXI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 6, 2015
07:04 EDTGTXIGTx says first patient enrolled in Phase 2 trial of TNBC treatment
GTx announced the enrollment of the first patient into its Phase 2 clinical trial of enobosarm to treat women with advanced, androgen receptor positive, triple negative breast cancer, or TNBC. Enobosarm is the company's lead product candidate and is also being evaluated in a separate Phase 2 clinical trial to treat estrogen receptor positive, AR+ breast cancer, which the company recently announced had also enrolled its first patient. The open-label, multi-center, multinational Phase 2 clinical trial will evaluate the efficacy and safety of orally administered enobosarm in up to 55 women with advanced, AR+ TNBC. Patients will receive 18 mg of enobosarm once daily for up to 12 months. The initial stage will be assessed among the first 21 evaluable patients. If at least 2 of 21 patients achieve clinical benefit at week 16, then the trial will proceed to the second stage of enrollment of up to a total of 41 evaluable patients. Clinical benefit is defined as a complete response, partial response, or stable disease, as measured by Response Evaluation Criteria in Solid Tumors at 16 weeks. The trial, which is being conducted under the leadership of Dr. Hope Rugo from the University of California at San Francisco, will include investigators from more than 40 clinical trial sites in the U.S. and abroad.
September 29, 2015
07:02 EDTGTXIGTx announces enrollment of first patient in Phase 2 Enobosarm trial
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use